Reconnoitering Mycobacterium tuberculosis lipoproteins to design subunit vaccine by immunoinformatics approach by Naeem, Muhammad Ahsan et al.














Reconnoitering Mycobacterium tuberculosis lipoproteins to 
design subunit vaccine by immunoinformatics approach 
Muhammad Ahsan Naeem#1*, Muhammad Muzammal Adeel#2, Ayesha Kanwal3, Sajjad Ahmad4, Waqas 
Ahmad1, Qaiser Akram1, Asif Saleh1 , Waqas Ahmed5 
                                                                                                                             
ackground: Tuberculosis is an aerosol transmitted disease of human beings caused by Mycobacterium 
tuberculosis (Mtb). The only available vaccine for Mtb is Bacillus Calmette-Guérin (BCG). Currently no 
alternative or booster is available for BCG. The objective of this predictive approach was based on binding 
of MHC-I and MHC-II and B cell epitopes of Mtb for mouse host.  
Methods: Immunoinformatics approach was used to design subunit vaccine (SV) by joining 8 MHC-I bindings, 
6 MHC-II bindings, and 8 B-Cell epitopes with AAV, GPGPG, and KK amino acid linkers, respectively. The 
efficacy of the SV was enhanced through Mtb protein Rv3763 (LpqH, PDB ID= 4ZJM) as an adjuvant at the N-
terminal of SV. The in silico analyses evaluated the SV to predict allergenicity, antigenicity, and physico-chemical 
properties.  
Results: Predictions revealed that SV is non-allergic and highly antigenic. The physico-chemical analysis 
showed that the SV was stable and basic in nature. The three-dimensional structure of SV was stable with a 
high binding affinity against the mouse TLR2 receptor. In silico cloning suggested the effective transformation of 
SV into the eukaryotic expression vector.  
Conclusion: This study permits preclinical validation of the designed SV in mouse host to confirm its 
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Bacille Calmette-Guérin (BCG) is the only available 
attenuated strain of Mycobacterium bovis against 
Tuberculosis (TB) [1]. As a vaccine, BCG can prevent 
neonates and children from the spread of TB [2]. 
However, the use of BCG vaccine has some severe 
limitations, as its overall efficacy is still in question [3, 4]. 
Several controversies about BCG include; failure to 
provide protection against pulmonary TB in adults, the 
absence of a booster dose, and difficulty in the 
differential diagnosis between diseased and vaccinated 
individuals by standard diagnostic test e.g. tuberculin 
skin test [5, 6]. Consequently, Mtb has undergone a 
dormant state in most cases after BCG vaccination and 
is associated with latent chronic infection development 
[7]. The latent Mtb becomes active when a person's 
immune status becomes weak, e.g., individuals with 
genetic immune defects, aged people, and people taking 
immunosuppressant drugs [6]. To overcome these 
issues of the currently available vaccine, the 
development of an alternative vaccine is essential. It is 
necessary to design a vaccine that is safer, more 
immunogenic, and induces long-lasting protection. An 
answer to this could be a multi-epitope subunit vaccine 
(SV), which is a substitutive approach to immunization. It 
identifies the peptide epitopes on immunogens and 
generates the immunogenic response [6]. For this 
purpose, synthetic versions of peptide epitopes have 
been used for engineering the vaccine. Contrary to 
routine vaccines, SV are non-infective, synthetic, 
possess zero risks of pathogen activation, and are free 
from unwanted effects, which are common while using 
whole organism attenuated vaccine [6].  
Mtb lipoproteins are a diverse class of membrane-
bound proteins with multiple functions [8]. These proteins 
have signal peptides which help in their secretion out of 
a bacterial cell and may cause post-translational 
modification in the host cell [8]. Immunoinformatics is a 
newly developed approach that predicts 
thermodynamically stable linker joined multi-epitopes 
novel vaccine(s) significantly less cost and time. We 
have used this approach in our study to predict MHC-I, 
MHC-II binding, and B cell epitopes to design a SV 
against tuberculosis. This vaccine was evaluated 
computationally for its physico-chemical characteristics, 
structure validation, antigenicity, allergenicity prediction, 
and in silico cloning in the eukaryotic expression vector. 
This study will help to provide a new immunogenic 
vaccine that may have the ability to induce the immune 
response against tuberculosis if evaluated in animal 
model, by complementing or boosting BCG challenges. 
Methods 
Collection of Mycobacterium tuberculosis protein 
sequences for vaccine design 
Primary sequences of 89 lipoproteins of Mycobacterium 
tuberculosis H37Rv were retrieved from Mycobrowser 
(database of Mycobacterium spp.) in FASTA format. 
These protein sequences were employed for scheming 
multi-epitope SV construct potentiated against TB 
infection. Experimentally known crystal structure of 
Mycobacterium tuberculosis Rv3763 (LpqH, PDB ID= 
4ZJM) TLR2 agonist protein and its primary sequence 
were retrieved from Protein Data Bank (PDB) [9], and 
Mycobrowser database respectively, to be used as an 
adjuvant. 
Prediction of epitopes 
MHC-I binding epitopes for all the selected lipoproteins 
of Mtb were predicted using Immune Epitope Database 
(IEDB) resources [10]. “IEDB recommended 2.19” 
prediction method. Six MHC alleles (H-2-Db, H-2-Dd, H-
2-Kb, H-2-Kd, H-2-Kk, H-2-Ld) each of 9-mer in length 
were selected, and peptides were sorted based on their 
lowest percentile rank. Similarly, the IEDB tool 
(http://tools.immuneepitope.org/mhcii/) [11] was 
recruited for predicting MHC-II binding epitopes. Default 
parameters were used against the mouse (host) with 
locus H-2-I. All three alleles, namely, H2-IAb, H2-IAd and 
H2-IEd, were selected for this locus. 15-mer length MHC-
II epitopes for mouse alleles were predicted for all the 
lipoproteins. B cell linear epitopes were predicted using 
ABCPRED server for the ultimate SV design. ABCPRED 
(http://crdd.osdd.net/raghava/abcpred/ABC_submission
.html) [12] with threshold >0.9 and epitope length of 20 
amino acids was used.  
Multi-epitope SV construct 
Epitopes of lowest percentile rank (high binding affinity), 
8 of MHC-I and 6 of MHC-II, were joined together with 
AAY and GPGPG amino acid linkers, respectively. 8 B 
cell epitopes with score ≥ 0.95 were selected and joined 
with KK amino acid linker to form the final vaccine 
construct. Therefore, mouse TLR2 (Uniprot ID: 
Q9QUN7) agonist Rv3763/LpqH Mtb protein [9] was 
selected as an adjuvant to augment the antigen-specific 
immune reactions. Moreover, a 13 amino acid sequence 
(AKFVAAWTLKAAA) known as PADRE sequence was 
concatenated at the start and the end of the epitope 
sequence of the vaccine to enhance its efficacy [13, 14]. 
The final SV consisted of 593 amino acids. 
Physiochemical parameter, allergenicity, and 
antigenicity predictions of SV construct 
Physicochemical parameters of the vaccine were 
determined by using ProtParam [15] web server, a part 
of Expert Protein Analysis System (EXPASY). Various 
parameters were predicted using this tool, including; 
theoretical pI, estimated half-life, molecular weight (kDa), 
grand average of hydropathy (GRAVY), and aliphatic 
index. AlgPred web tool [12] was applied for the 
prediction of allergenicity of SV. AlgPred uses combined 
algorithms (SVMc+ IgEepitope + ARPs BLAST+ MAST) 
approach to give highly accurate results. Allergenicity 
measurement of a protein is essential because most of 
the allergens are protein in nature and can cause 
sensitization or severe allergic reactions. Thus, the 
predicted vaccine construct must be free from the 
allergenic nature. For antigenicity index prediction, 
ANTIGENpro tool was applied, as this tool is efficient and 
accurate. ANTIGENpro performs prediction by using 
primary protein sequences regardless of any pathogen 
and without performing their alignment. For categorizing 
a protein as antigenic or non-antigenic, ANTIGENpro 
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uses a support vector machine (SVM) algorithm based 
on its microarray data.  
Prediction of SV secondary structure  
For secondary structure prediction of SV protein, 
PSIPRED web-based server 4.0 
(http://bioinf.cs.ucl.ac.uk/psipred/) was applied, which 
uses Psi-BLAST i.e., Position-specific iterated BLAST 
method to find out the closest identical sequences of 
related protein templates or sequences.  
Tertiary structure prediction of SV construct and 
molecular docking with TLR2 immune receptor  
Tertiary structure prediction of the vaccine is crucial 
because it is more stable, and this stability is achieved 
by decreasing the energy of protein molecules. Three-
dimensional SV vaccine structure was designed and 
configured by RaptorX server at default parameters. 
Energy minimization and structure visualization were 
carried out by (University of California, San Francisco) 
UCSF Chimera tool. To perform the interaction analysis, 
a molecular docking approach was used in which SV 
construct was docked against mouse TLR2 (PDB ID: 
2Z7X) using PatchDock 
(http://bioinfo3d.cs.tau.ac.il/PatchDock/) [16] followed by 
the rescoring and refinement of docked solutions through 
FireDock (Fast Interaction Refinement in Molecular 
Docking) server. FireDock predicts the ten best way-outs 
based on binding score. Interacting amino acids of SV 
and TLR2 receptors were visualized through the LigPlot 
tool.  
It is crucial to detect whether a designed vaccine has a 
binding affinity with its receptor or not [17]. If the receptor 
can recognize Mtb, then it leads to an immunogenic 
response in the host [18].   
Reverse translation, codon optimization and in silico 
cloning of SV construct 
To check the expression of the designed SV construct in 
the eukaryotic system, we first reverse-translate our 
protein using Sequence Manipulation Suite: reverse 
translation tool, and the resulting sequence was used for 
codon optimization. Java Codon Adaptation Tool (JCAT) 
[19] was used to optimize the codon of SV construct in 
eukaryotic organisms (Mus musculus). Three additional 
parameters, including prokaryote ribosome binding site, 
restriction enzymes cleavage sites, and avoid the rho-
independent transcription termination, were selected for 
appropriate codon optimization, followed by XhoI 
restriction site digestion and  cloning  into adeno-
associated virus vector (pAAV) by using SnapGene tool. 
Results 
Epitopes collection and design of SV  
After predicting MHC-I binding, MHC-II binding, and B 
cell epitopes, the immuno-informatics approach was 
used to construct a SV. MHC epitopes were selected 
according to the instructions of IEDB i.e. low percentile 
epitopes have a high binding affinity with MHC 
molecules. Thus, for percentile rank, a threshold of less 
than or equal to 0.3 was self-created for shortlisting of 
epitopes of different proteins. The shortlisted MHC-I and 
MHC-II binding epitopes for lipoproteins are presented in 
table 1 and 2, respectively. B cell epitopes were selected 
based on their highest score. To shortlist these epitopes, 
a self-created threshold of more than 0.9 score was used 
in table 3.   
Protein 
Name 





LprB LGPHFSFSW 91 99 H-2-Dd 0.1 268.42 
LpqK YAHTNYLLL 188 196 H-2-Db 0.1 4.36 
LpqM YQLVNAFFS 140 148 H-2-Db 0.1 106.03 
LprM LELQWGRTI 340 348 H-2-Kk 0.1 5.74` 
pstS3 DGPTLAKIF 148 156 H-2-Dd 0.1 1085.98 
ugpG RGPQSWSEF 172 180 H-2-Dd 0.1 217.85 
proX ASCANADPL 25 33 H-2-Db 0.1 19.28 
Table 1: Predicted MHC-I binding epitopes. 
(≤ 0.3 percentile rank as threshold, against mice alleles H-2- (Db, Dd, 
Kb, Kd, Kk, Ld) 
Protein 
Name 
Peptide Seq Start End Allele Percentile Rank 
LpqU RRWLRAVAVIGATAM 4 18 H2-IAd 0.01 
LprI ALAHRRSAALEAAQS 66 80 H2-IAd 0.01 
LpqO RRGARMAALLAAAAL 4 18 H2-IAd 0.01 
LppN VYLRAPVAVDAAVVS 98 112 H2-IAd 0.01 
LpqF RRAGRRMLALSAAAA 9 23 H2-IAd 0.01 
GlnH MTRRALLARAAAPLA 1 15 H2-IAd 0.01 
Table 2: Predicted MHC-II binding epitopes  
(≤ or = 0.3 percentile rank as threshold, against mice alleles H-2-I （
Ab, Ad, Ed) 
Lipoprotein Epitope Score Start position 
LppJ LDHSYGEMILDGECRNTTDH 0.95 152 
LpqW GIDWIGPGFNPHLLSDLSPV 0.95 58 
LprD NAYLAELAKDDARKQNRTTA 0.95 107 
LpqM LPMQSPWTALRTACLTGVAH 0.96 408 
Rv2585c RTRRALALCVPRDAIARDAG 0.95 330 
Rv2864c SPFGMALVAATVAAGKTPVP 0.95 481 
LppL PTIEPAQPAVSPPTSQDPAG 0.95 40 
GlnH MADQPYGVGINLDNTGLVRF 0.95 271 
Table 3: Predicted B cell epitopes of lipoproteins. 
These epitopes were linked together by using a linker 
in such a way that MHC-I epitopes are linked by AAY, 
MHC-II by GPGPG, and B cell epitopes by KK linkers, 
respectively. Further, the Rv3763 (LpqH, PDB ID= 
4ZJM) protein of Mtb [9] was used as an adjuvant at N-
terminal to improve the immunogenicity of the vaccine. A 
sequence of 13 amino acids, the PADRE sequence [14], 
was incorporated after adjuvant and at the end of the last 
epitope to further enhance vaccine efficacy (Fig. 1). 
 
Figure 1: Schematic diagram of final SV construct. The multi epitope 
vaccine sequence consisted of 593 amino acid residues. Among these, 
the first 159 residues are represented as an adjuvant followed by MHC-
I binding epitopes (160–280 amino acids), MHC-II binding epitopes 
(281–400 amino acids) and B cell epitopes (401-593 amino acids).  
This Diagram clearly showed that the EAAAK linker 
joined the adjuvant and MHC-I binding epitopes, while 
MHC-I and MHC-II binding epitopes were connected 
through AAY and GPGPG linkers. The MHC-II binding 
 
                        Advancements in Life Sciences  |  www.als-journal.com  |  July 2021  | Volume 8  |  Issue 3                                     303         
 





epitope and first B cell epitope were joined by a GPSL 
linker. 
Allergenicity, Antigenicity and Physicochemical 
Predictions of vaccine 
The results of allergenicity prediction by AlgPred 
revealed that SV is non-allergen with a -0.69 score, 
which is less than the threshold value of -0.4. However, 
antigenicity prediction by ANTIGEN pro revealed that SV 
is a probable antigen with a score of 0.7730, which is 
more than the threshold value of 0.4. Physico-chemical 
properties were obtained by using ProtParam, which 
showed that SV protein has a total of 593 amino acids 
with a molecular weight of 60.1 kDa. The theoretical PI 
is 9.89, which depicts that our SV is basic in nature, while 
the computed instability index of SV is 37.31, 
demonstrating that SV is stable in nature. The grand 
average of GRAVY value is -0.018 which means that SV 
is hydrophilic i.e. easily dissolvable in water. 
Secondary Structure Prediction 
The secondary structure of SV protein was predicted by 
PSIPRED server (Fig. 2). The results were obtained in 
the form of a strand (yellow), helix (pink), and coil (grey 
line), which are presented with different color schemes. 
Percentage of strand, helix and coil in SV is 17.87%, 
40.64%, and 41.49%, respectively.  
Prediction and validation of the tertiary structure in 
protein 
This pattern of the protein was predicted through 
RaptorX and the resultant SV has been shown in Fig. 3a. 
3D model of SV was predicted for 3 domains at different 
amino acid, including; domain 1 (1-268) 2.40 x 10-10, 
domain 2 (366, 581) 8.60 x 10-5and domain 3 (269, 365) 
1.20 x 10-4. The calculated overall un-normalized GDT 
(uGDT) of SV structure was 347. 100% residues (593) in 
the SV protein were modeled and 11% (64) residues 
were in the disordered region. 
The quality or checking of any error in the 3D model of 
protein was performed using ProSA-web [26]. ProSA-
web calculated Z-score -1.52 for SV (Fig. 3b). The 
Ramachandran plot validated the tertiary structure of SV. 
The plot showed  (Fig. 3c) that 423 out of 593 (87.9%) 
residues were in the favored regions [A, B, L], 40 
residues (8.3%) were in additional allowed regions 
[a,b,l,p], 7 (1.5%) residues were in generously allowed 
regions [~a, ~b, ~l, ~p] and only 11 (2.3%) residues were 
in disallowed regions. The number of glycine residues 
(shown in a triangle) was 69, and the number of proline 
was 41. Thus, this tertiary structure is of good quality as 
most of its residues are present in the most favored 
regions. 
Docking of SV with TLR2 receptor  
Molecular docking was performed through PatchDock 
server. SV protein was docked with mouse TLR2 
receptor containing adjuvant. PatchDock server 
produced docked solutions based on refined geometry 
and electrostatic affinity of the protein surface.  Resulting 
docked complexes were subjected to Fast Interaction 
Refinement in Molecular Docking (FireDock) server for 
refinement and re-scoring based on respective binding 
energy. The top-ranked complex was selected, having 
global energy -7.46 and attractive Van Der Waals 
interactions score -11.71 (Fig. 4a).   
 
Figure 2: Yellow color blocks representing stand, pink; Helix and 
Gray lines representing coils of the secondary structure composed for 
SV. 
 
Figure 3a: The multi-epitope vaccine and its 3D model that has been 
procured refinement and homology modeling.
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Figure 3b: 3D structure showing Z-score and PROSA validation (-
1.52). 
 
Figure 3c: Plot analysis through Ramachandran model and various 
percentages of structures have also been mentioned in the lower set of 
the image.  
U-shaped binding pocket amino acid residues (Glu310, 
Arg340, Arg395, Glu363, Gln390, Leu 525, Gln526 and 
Asn552) of TLR2 receptor were involved in hydrogen 
bonding with SV residues (Gly45, Ala46, Ser48, Asn93, 
Thr116, Gly117, Asn120, and Ala121) after molecular 
docking. The docked result is shown in Fig. 4b.  
 
Figure 4a: Mouse TLR2 is docked with Mycobacterium tuberculosis 
Rv3763 (PDB ID: 4ZJM) adjuvant of SV construct. 
 
Figure 4b: Closed view of SV and mouse TLR2 receptor docked 
complex. SV as a ligand have adjuvant (red), epitopes (yellow), linkers 
(white) and PADRE sequence (Cyan) whereas TLR2 receptor has been 
shown in green color. 
Reverse translation and codon optimization 
SV sequence was reverse translated to the nucleotide 
sequence. The total length of the reverse translated 
sequence is 1794 bp. Then this sequence was codon-
optimized for expression in the mice host. Codon 
adaptation index (CAI) value of optimized sequence was 
0.71, GC content of improved sequence was 73.24 and 
GC content of Mus musculus was 41.76%. Graphical 
representation of optimized or adapted sequence is 
shown in Fig. 5. 
In silico optimization and cloning of vaccinal protein 
The SV nucleotide sequence was codon 
adapted/optimized according to the mammalian (mouse) 
vector by introducing BsmI and BamHI restriction sites in 
N- and C-terminal of the vaccine sequence. Finally, the 
improved sequence with restriction sites was adjusted in 
the pAAV-CMV-eGFP vector by means of SnapGene 
tool to guarantee protein expression in the vaccine (Fig. 
6). 
 
Figure 5: Graphical presentation of codon optimized sequence. Red 
peaks indicate that almost every codon has been optimized. Y-axis 
represents the relative addictiveness of each codon. 
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Figure 6: In silico cloning of final SV nucleotide sequence into 
eukaryotic expression vector (pAAV-CMV). Gray part labeled as 
“lipoprotein SV” has represented the vaccine insert. 
Discussion 
Vaccination is an efficient way to control infectious 
diseases and improve public health [20]. Now-a-days, 
much genomic, transcriptomic, and proteomic 
information is available for Mtb and other pathogenic 
microbes. Computational approaches were applied 
using this information to identify potential antigenic 
targets [21]. In our study, we focused to design a SV from 
89 lipoproteins of Mtb. Instead of using the whole 
organism as a vaccine agent, only the immunogenic part 
of these proteins was used to construct the vaccine. 
Lipoproteins of Mycobacterium tuberculosis belong to 
the functionally broad class of membrane-bound proteins 
[8]. These proteins are involved in providing virulence 
and immunogenicity to Mtb as the interruption in the 
biosynthesis of lipoproteins leads to the weakening of 
Mtb activity [22].  
Mtb epitopes that showed resemblance with the host 
proteome were identified. The protein sequences of 
lipoproteins were imperiled to BLASTp search against 
the human host proteome. These proteins of Mtb did not 
show any sequence homology with human proteins. 
Thus, these proteins could be excellent immunogenic 
targets for synthesizing vaccines against Mtb. In this 
study, epitopes for B and T cells of 89 lipoproteins were 
predicted. Epitopes of T cells are presented on the 
surface of antigen-presenting cells by combining with 
MHC molecules [23]. MHC molecules are antigen-
presenting moieties, mainly of two types, i.e. class I and 
class II [24]. Class I molecules, mainly represented to 
cytotoxic T lymphocytes or CD8+ T cells, can be 
presented on any kind of nucleate cell that represents 
the endogenous processed protein or the engulfed 
processed protein that were digested and processed in 
cytosolic pathways [25]. Class II molecules are mainly 
combined and present exogenous proteins, such as 
pathogens’ surface proteins. These are processed in the 
cellular endocytic pathways and presented to helper 
CD4+ T lymphocytes [20]. 
The immunoinformatics approach to analyze SV 
demonstrated that our final SV protein has a tremendous 
binding affinity with MHC-I, MHC-II, and B-cell epitopes 
based on structural and physicochemical characteristics. 
Model quality of the 3-dimensional vaccine protein 
structure predicted by homology modeling suggested the 
refined amino acid distribution. Ramachandran plot 
shows that most of the vaccine residues are present in 
the favorable region, and very few are located in the 
disallowed regions. This showed that the overall model 
quality of protein structure is acceptable.  
The conformational stability of the vaccine was done 
by docking with the TLR2 receptor to determine the 
immunological response of the vaccine construct. 
Energy consumption was reduced to decrease the 
potential energy of the protein-receptor complex system. 
This process also keeps the dismissed arrangements of 
protein structure by replacing a few subcellular 
structures in the protein to yield appropriate 
stereochemistry of a stable protein framework.   
The optimum level of translation expression of a 
vaccine in the eukaryotic system is necessary for vaccine 
functionality. The process was carried out by codon 
optimization of the nucleotide sequence of the vaccine to 
refine transcriptional and translational efficiency [26]. 
The parameters used for analyzing the codon 
optimization are; total GC content of DNA sequence and 
CAI. The important requirement for various physiological 
and biochemical studies is the solubility of the 
overexpressed recombinant protein in the eukaryotic 
system. Augmenting the strength of proteins is a 
domineering target in several mechanical and bio-
medical uses. Therefore, unique immunoinformatics 
tools were incorporated in the current study for a safe, 
potentiated and immunogenic SV design which may 
have the controlling ability against tuberculosis. 
Tuberculosis disease has become an intense problem 
at the international level. It causes many deaths in the 
developing states of Asia and Africa, and there is still no 
permanent control and remedial measure for the 
disease.  The immunoinformatics technique was used for 
the development of a multi-epitope SV. This work begins 
with the recovery protein sequences of 89 Mtb 
lipoproteins. After that the immunogenic B- and T-cell 
epitopes were predicted, epitopes were joined by linkers 
for the effective separation of epitopes in in-vivo system, 
adjuvant was added in the start to enhance the 
immunogenicity and then design the SV to get the cell-
mediated and humoral immunity. Allergenicity and 
antigenicity parameters were predicted to confirm that 
the vaccine is non-reactive in nature. The binding affinity 
with the host cell receptor was evaluated by molecular 
docking. Finally, the effective expression of SV protein 
was made sure by in silico cloning. Furthermore, the 
recommendation obtained from this study declares that 
the proposed vaccine requires experimental validation to 
analyze the efficacy of the vaccine in the sense of 
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